中信证券再次助力乐普生物成功完成新股配售

中信证券发布
11 Jul

2025年7月11日,乐普生物科技股份有限公司(以下简称乐普生物,2157.HK)成功完成4.71亿港元新股配售,中信证券担任联席整体协调人和联席配售代理。中信证券发挥全球网络优势展现强大配售实力乐普生物聚焦肿瘤治疗,产品管线覆盖免疫治疗、ADC靶向治疗和溶瘤病毒药物三大领域,本次配售所得款项将用于核心产品的商业化、临床试验推进以及新产品管线的研发,在扩大股东基础、资本基础的同时提升财务状况及...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10